A Step-by-Step Guide to Adding Peptides to Your Ketamine Practice
Peptide therapy is moving from biohacker circles into clinics, med spas, and integrative practices. For ketamine clinics, the interest makes sense — cash pay patients, injection infrastructure, and a patient base already asking about mood, recovery, sleep, and optimization.
But adding peptides is not as simple as choosing a few compounds and building a service page. The regulatory landscape is changing quickly. The evidence varies widely by compound. Sourcing decisions create real liability. This guide walks through what ketamine clinics need to do before adding peptide therapy — from regulatory review and pharmacy sourcing to protocols, pricing, staff training, and launch planning.
Here’s An Overview
| Step | What You Do | Why It Matters | When |
|---|---|---|---|
| Readiness Audit | Review provider authority, malpractice coverage, cold storage, consent forms, and clinical workflows | Helps identify compliance, insurance, and operational gaps before launch | Weeks 1 to 2 |
| Peptide Menu | Choose 2 to 3 initial protocols that fit your current patient base | Keeps the launch focused and prevents staff from managing too many variables at once | Weeks 1 to 2 |
| Regulatory Review | Verify the current status of each compound before prescribing, stocking, or marketing it | Peptide legality is compound specific and subject to change | Weeks 1 to 3 |
| Pharmacy Sourcing | Work only with licensed 503A or 503B compounding partners and request documentation | Sourcing is one of the highest risk areas for peptide programs | Weeks 3 to 4 |
| Clinical Protocols | Build dosing guides, screening forms, monitoring schedules, lab policies, and discontinuation criteria | Creates a more defensible clinical record and reduces staff decision fatigue | Weeks 5 to 6 |
| Staff Training | Train clinical and administrative staff on storage, preparation, injections, patient education, and scheduling | Front desk and clinical teams both influence patient trust and conversion | Weeks 5 to 6 |
| Legal and Compliance | Update consent forms, review marketing claims, confirm malpractice coverage, and consult healthcare counsel | Protects the practice from avoidable regulatory and liability exposure | Weeks 5 to 7 |
| Pricing and Packaging | Model pricing based on pharmacy cost, provider time, labs, follow up, and patient education | Peptides can support recurring revenue, but only if pricing reflects the real cost of care | Week 7 |
| Soft Launch | Start with existing patients before expanding to broader marketing | Existing patients already trust your team and give you a safer testing ground | Weeks 7 to 12 |
The Regulatory Landscape Comes First
Regulatory status current as of May 2026. Peptide compounding rules are changing quickly — verify the current status of any compound with your pharmacy partner and healthcare counsel before acting on this guide.
This guide is for operational planning and education. It is not legal, medical, or regulatory advice. Clinics should consult qualified healthcare counsel, their malpractice carrier, their state medical and pharmacy boards where appropriate, and their pharmacy partners before prescribing, administering, dispensing, stocking, or marketing any peptide therapy service.
Before opening pharmacy accounts or training staff, clinics need to understand where peptide regulation stands now.
Peptide legality is not one size fits all. A compound may be widely discussed online and still be inappropriate to offer. It may be available from a vendor and still create risk for the clinic. It may be under FDA review without being FDA approved.
Compounded drugs are not FDA approved. FDA does not review them for safety, effectiveness, or quality before they are marketed. For clinics, this does not mean compounded medications are never appropriate.
It does mean that sourcing, consent, documentation, and patient selection matter.
For clinics, the key question is not whether a peptide is popular, available, or under discussion at FDA. The key question is whether the specific substance, route, formulation, pharmacy model, and intended use fit within a lawful compounding pathway at the time the clinic offers it.
The regulatory status of several commonly discussed peptides is in active flux. In April 2026, FDA signaled a shift in its handling of several peptide-related bulk substances that had previously appeared in Category 2. FDA has scheduled a July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting to discuss seven peptide-related bulk substances for potential inclusion on the 503A Bulks List: BPC-157, KPV, TB-500, MOTs-C, Emideltide/DSIP, Semax, and Epitalon. That meeting does not, by itself, make these substances lawfully compoundable. A favorable committee discussion would still require FDA action through the appropriate regulatory process. Two caveats matter for clinics: the committee’s recommendation is non-binding, and even a favorable outcome requires formal notice-and-comment rulemaking that can take a year or more before any peptide is lawfully compoundable. This review applies only to 503A compounding — the separate 503B outsourcing-facility bulks list is not part of it. Clinics that lived through the compounded GLP-1 shortage already saw how fast this landscape can shift; for a parallel example, see our breakdown of whether compounded GLP-1s are legit.
The practical takeaway for ketamine clinics is simple: do not assume that a peptide is legally compoundable because patients are asking about it, competitors are advertising it, or a pharmacy is willing to discuss it. Verify the current status of each compound before offering it.
What Clinics Should Verify Before Offering Any Peptide
Here is what to work through before adding any compound to your menu. Here is what to watch for on your website and in patient communications.
| Question | Why It Matters |
|---|---|
| Is this compound FDA approved for any indication? | FDA approved products are different from compounded peptides and should not be discussed the same way. |
| If FDA approved, is the clinic using it for the approved indication? | Off label use may be legal, but it requires careful documentation and consent. |
| If compounded, is the compound currently eligible for lawful compounding? | Peptide status can shift based on FDA review, pharmacy rules, and sourcing standards. |
| Is the intended use supported by human clinical evidence? | Many popular peptides have more animal, preclinical, or anecdotal data than strong human evidence. |
| Will the clinic prescribe, administer, dispense, or stock the product? | Each model creates different operational and compliance obligations. |
| Does malpractice coverage clearly include this service? | Standard malpractice policies may not cover compounded or off label peptide protocols. |
| Can the clinic document lot number, source, COA, storage, and beyond use date? | Documentation protects both patients and the practice. |
| Has marketing language been reviewed? | Peptide claims can create FDA, FTC, state board, and malpractice risk. |
State Rules Still Matter
Federal compounding rules are only part of the analysis. Clinics should also review state medical board rules, pharmacy board rules, nurse practitioner and physician assistant scope of practice, supervision requirements, office-use restrictions, telehealth prescribing rules, advertising rules, and corporate practice of medicine issues where applicable. Multi-state clinics should not assume a peptide protocol approved in one state can be copied into another.
Step 1: Evaluate Your Clinic’s Readiness
Many ketamine clinics already have part of the infrastructure needed to add peptide therapy. They may already manage cash pay care, educate patients about novel treatments, and operate with systems for consent, intake, follow up, and monitoring. Some may already have experience with compounded medications.
Those advantages do not replace a readiness audit. Start with four areas.
First, confirm prescribing authority. MDs and DOs generally have broad prescribing authority, but state rules, medical board expectations, supervision requirements, and scope of practice issues still apply. Nurse practitioners and physician assistants may face different rules depending on state, supervising physician relationship, and clinic model.
Second, review storage and handling. Many peptides are temperature sensitive. Some require refrigeration. Some require reconstitution. Some have strict beyond use dating after preparation. A clinic that cannot document storage conditions should not stock injectable peptides.
Third, confirm malpractice coverage. Do not assume your existing policy covers peptide therapy, compounded medications, off label protocols, or wellness services. Get written confirmation from your carrier. If coverage is excluded or unclear, speak with a broker familiar with integrative medicine, med spa, or cash pay clinic models.
Fourth, review informed consent. Existing ketamine consent forms will not cover peptide therapy. Clinics need separate peptide consent documents that explain the investigational nature of many compounded peptides, known and unknown risks, expected monitoring, alternative options, and pharmacy sourcing.
Step 2: Choose a Focused Peptide Menu
Do not try to offer every peptide on day one. A narrow launch is easier to train, monitor, document, and explain to patients. It also helps the clinic collect early data on interest, adherence, adverse events, and operational burden.
For ketamine practices, the most natural categories are mood and cognition, pain and recovery, general optimization, and sexual health. Each comes with different clinical and regulatory considerations.
This table is not a recommended formulary. These are examples of compounds patients may ask about, and clinics should verify the legal status, evidence base, route, formulation, sourcing, and patient-specific appropriateness of each compound before offering it.
| Category | Compounds Patients May Ask About | Why Patients Ask About It | Clinic Caution |
|---|---|---|---|
| Mood and cognition | Semax, Selank | Patients may be seeking mental health, focus, or cognitive support | Avoid claiming these peptides enhance or extend ketamine’s effects without compound specific evidence and legal review. |
| Pain and recovery | BPC-157, TB-500 | Many ketamine patients have chronic pain, injuries, or inflammation concerns | High patient awareness does not equal FDA approval or strong human evidence. Regulatory status must be verified before use. |
| General optimization | Ipamorelin, CJC-1295, Sermorelin | Patients interested in sleep, energy, body composition, or longevity | Growth hormone related protocols require careful screening, lab monitoring, and patient selection. |
| Sexual health | Bremelanotide / PT-141 | Some patients ask about libido, sexual function, or hormone adjacent concerns | Vyleesi is FDA approved for one specific indication. Compounded or off label use should not be marketed as equivalent. |
The strongest launch strategy is usually not to offer everything. Start with the fewest protocols your team can deliver safely, consistently, and defensibly.
Step 3: Understand 503A and 503B Pharmacy Models
Peptide sourcing is one of the highest risk areas in this category. Clinics should work only with properly licensed compounding partners. That means understanding the difference between 503A pharmacies and 503B outsourcing facilities.
Pharmacy licensure is only the first step. Clinics should not treat 503A or 503B status as a blanket green light. The clinic still needs to confirm whether the pharmacy can lawfully compound the specific peptide, in the specific formulation and route, for the clinic’s intended model.
| Feature | 503A Pharmacy | 503B Outsourcing Facility |
|---|---|---|
| Primary Oversight | State boards of pharmacy, with FDA oversight in certain areas | FDA registered outsourcing facility |
| Prescription Model | Patient specific prescription required | May produce certain compounded drugs without individual prescriptions |
| Typical Use | Individualized patient prescriptions | Office stock and larger scale production, when permitted |
| Manufacturing Standards | Must meet applicable compounding standards | Subject to current good manufacturing practice requirements |
| Key Caution | Rules vary by state and compound | 503B status does not automatically make every peptide legal to stock or administer |
A 503B facility may simplify inventory and office stock. It does not automatically solve the legality question. A 503A pharmacy generally raises patient-specific prescription issues. A 503B outsourcing facility may support office-use models in some circumstances, but only if the product and bulk substance fit within the applicable 503B rules. The compound itself still must be appropriate under the applicable compounding framework. Verify both the facility and the substance.
Step 4: Build a Pharmacy Sourcing Checklist
Before ordering, ask every pharmacy for documentation. Clinics should not source peptides labeled “research use only,” “not for human use,” “research grade,” or similar language for patient care. This is part of the clinical safety process — not paperwork. Patients may never ask where a peptide came from. Regulators, insurers, plaintiff attorneys, and medical boards may.
At minimum, request: certificate of analysis for each lot, sterility testing documentation for injectables, endotoxin testing, potency testing, API supplier documentation, USP compliance information, beyond use dating, cold chain shipping protocol, state licensure, 503A or 503B status, recall history or recent FDA or state board actions, adverse event reporting process, and backup supply chain options.
Step 5: Build Clinical Protocols
Every peptide protocol should have a clinical packet before the first patient starts treatment. That packet should include a patient selection guide, contraindication checklist, dosing guide, medication preparation guide, storage and handling instructions, monitoring schedule, lab requirements, expected follow up cadence, adverse event documentation, discontinuation criteria, patient education language, and informed consent. For a patient-facing reference on baseline and monitoring labs, see what lab work peptide therapy actually requires.
Clinics should also decide who owns each step. Who determines eligibility? Who discusses risks and alternatives? Who teaches injections? Who reviews labs? Who handles adverse events? Who approves refills?
A peptide progra
m can create recurring revenue. It also creates recurring clinical responsibility.
Step 6: Train the Whole Team
Peptide training should not stop with the prescribing provider. Clinical staff need practical training on storage, reconstitution, injection technique, documentation, adverse event escalation, and patient education. Administrative staff need a different kind of preparation.
They do not need to explain peptide mechanisms. They do need to know what the clinic offers, what they should not say, who is a good fit for a consultation, and when to route questions to a clinician. Many peptide conversations will start at the front desk or during scheduling. Give the team a simple FAQ and a clear script.
For example: “Peptide therapy is something our clinical team evaluates on a patient by patient basis. Not every peptide is appropriate for every patient, and some compounded peptides have different regulatory and evidence considerations. The first step is a consultation so the provider can review your goals, history, medications, and whether this is clinically appropriate.”
That answer is simple, accurate, and much safer than promising outcomes.
Step 7: Review Consent, Insurance, and Marketing Claims
This is where many clinics get into trouble. A clinic may build a thoughtful clinical protocol and then undermine it with careless website copy, social posts, intake scripts, or email marketing.
Avoid language that suggests compounded peptides are FDA approved or clinically proven for broad wellness outcomes. Do not imply they are equivalent to approved drugs or guaranteed to produce results.
Consent forms should also be specific to the product and protocol. They should explain whether the product is FDA approved or compounded, the limits of human evidence, known and unknown risks, route-specific risks, alternatives including FDA-approved options where applicable, what to do in the event of an adverse reaction, pharmacy sourcing where appropriate, financial responsibility, and the fact that treatment does not guarantee benefit.
Avoid saying: FDA approved peptides (unless referring to a specific approved product and indication), clinically proven (unless citing strong compound specific evidence for the stated use), safe and effective when discussing compounded peptides broadly, guaranteed results, heals injuries, regenerates tissue, reverses aging, or extends the ketamine neuroplasticity window.
Clinics should also avoid branding compounded peptide products in a way that obscures the pharmacy source or implies the clinic manufactured the medication. Marketing should clearly distinguish between FDA-approved products, compounded medications, and investigational or off-label uses.
Consider language like: “Peptide therapy may be considered for appropriate patients after clinical evaluation.” “Some compounded peptides are not FDA approved.” “Evidence varies by compound, indication, and route of administration.” “Our clinic reviews each patient’s goals, medical history, medications, and risk factors before recommending treatment.”
This language is less flashy. It is also far more defensible.
Step 8: Price the Program Carefully
Peptide programs can create recurring patient relationships between ketamine treatment series. But pricing should reflect the real cost of care.
Model your pricing to include medication cost, pharmacy shipping, cold storage, provider consultation time, lab review, follow up visits, staff education time, injection training, documentation, adverse event management, malpractice exposure, marketing review, and patient support.
Some clinics may price peptide protocols as monthly programs. Others may separate the consultation, medication, labs, and follow up. Some may bundle peptides with ketamine maintenance or broader integrative care. The business case is strongest when pricing reflects clinical oversight, not just medication resale.
Step 9: Start With a Soft Launch
Your existing patient base is the best place to start. These patients already know your clinic, trust your providers, and understand cash pay care. Many may already be asking about peptides, longevity, recovery, or optimization.
A soft launch lets you test workflows before adding broad marketing. Start with a short email to existing patients, a provider led educational session, a one page patient handout, a consultation offer for appropriate patients, a limited number of early appointments, and a clear feedback process.
Do not start with a large paid campaign. Start with patients who already trust the clinic and can help surface operational gaps.
Step 10: Track the Right Metrics
Treat the peptide launch like any other clinical service line. Track consultation requests, consultation to start rate, most requested protocols, patient adherence, refill patterns, adverse events, patient reported outcomes, provider time per patient, medication cost, gross margin, net margin after clinical time, retention between ketamine maintenance visits, and referral activity.
This data tells you whether the program is clinically useful, operationally realistic, and financially worth expanding.
The 90 Day Peptide Launch Timeline
| Weeks | Milestone | Key Actions |
|---|---|---|
| Weeks 1 to 2 | Readiness and Selection | Complete readiness audit, choose initial protocol categories, review provider authority, identify insurance questions |
| Weeks 3 to 4 | Regulatory and Pharmacy Review | Verify compound status, consult legal counsel, evaluate 503A and 503B partners, request sourcing documentation |
| Weeks 5 to 6 | Protocols and Training | Finalize clinical protocols, consent forms, storage workflows, staff scripts, and adverse event procedures |
| Weeks 7 to 8 | Soft Launch | Offer consultations to selected existing patients, test workflows, collect feedback, refine documentation |
| Weeks 9 to 12 | Scale Carefully | Add website content, patient education materials, referral prompts, and broader marketing only after workflows are stable |
Some ketamine clinics may move faster if they already have compounding pharmacy relationships, trained clinical staff, and legal review in place. Others should move slower. The goal is not to add peptides as quickly as possible. The goal is to add them in a way the clinic can defend clinically, operationally, and legally.
The Bottom Line
Adding peptide therapy to a ketamine practice can make strategic sense. The patient base may overlap. The cash pay model may already exist. The clinic may already understand injection based treatments, patient monitoring, and nuanced consent conversations.
But peptides should not be treated as a simple add on. The better frame is not simply how quickly a ketamine clinic can add peptides. It is whether the clinic can evaluate, offer, document, and monitor peptide therapy safely, legally, and defensibly. The clinics best positioned to succeed will not be the ones that advertise the most compounds the fastest. They will be the ones that verify the regulatory status of each peptide, work with appropriate pharmacy partners, train their teams, document carefully, and communicate with patients in a clear and responsible way.
For ketamine practices, peptide therapy may become an important adjacent service line. The launch should start with compliance, not marketing.
